Rybrevant Faspro Gets Accelerated FDA Nod in Head and Neck Cancer & Tibsovo Lifts EFS in Fit AML

J&J's Rybrevant Faspro (amivantamab) won accelerated FDA approval in later-line head and neck cancer on a 42% single-arm response rate. A HOVON trial adding Tibsovo (ivosidenib) to intensive chemotherapy in IDH1-mutated AML showed a large interim event-free survival gain, though overall survival is not reported. The daily roundup covers ASH detail on Genmab and AbbVie's epcoritamab plus lenalidomide in lymphoma and Pfizer's Elrexfio (elranatamab) in myeloma, Boehringer Ingelheim's staged six-program deal with SBP Group, and the FDA's Nov 6 Zolgensma cancer-risk alert in spinal muscular atrophy. Akebia's VOCAL trial of Vafseo (vadadustat) in dialysis anemia closes this original November 5 edition, released on a delayed schedule.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.